<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755387</url>
  </required_header>
  <id_info>
    <org_study_id>EASTYLE</org_study_id>
    <nct_id>NCT04755387</nct_id>
  </id_info>
  <brief_title>Ticagrelor De-escalation Strategy in East Asian Patients With AMI</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ticagrelor as nonthienopyridine, direct-acting P2Y12 receptor antagonist, had significantly&#xD;
      greater platelet inhibition, which could reduce ischemic events at acute phase, however,&#xD;
      resulting in more incidence of bleedings than pro-drug P2Y12 receptor inhibitor during&#xD;
      chronic phase for management of acute myocardial infarction (AMI) following percutaneous&#xD;
      coronary intervention (PCI). Also, East Asians have higher response to potent agent, like&#xD;
      ticagrelor, when compared with Caucasians. With this in mind, East Asian patients will be&#xD;
      required optimal, potentially reduced dose of ticagrelor to improve the safety profile,&#xD;
      maintaining better vascular outcomes. Similarly, there are insufficient East Asian data on&#xD;
      the efficacy and safety of low-dose ticagrelor in real-word practice. Whether the&#xD;
      de-escalation strategy (ticagrelor 60/45 mg twice daily) are more adequate for clinical&#xD;
      practice in East Asian is unclear. Therefore, the investigators design the EASTYLE study,&#xD;
      hypothesis that low-dose ticagrelor would be more likely adequate for optimal antiplatelet&#xD;
      treatment without increasing ischemic and bleeding events in East Asian with AMI compared&#xD;
      with standard-dose ticagrelor. In the EASTYLE trial, further clinical data of de-escalation&#xD;
      strategy guided AMI management in East Asian will be provided.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In EASTYLE trial, the investigators aim to evaluate the efficacy and safety of de-escalation&#xD;
      strategy ticagrelor (60/45 mg twice daily), as compared with standard strategy ticagrelor (90&#xD;
      mg twice daily) in East Asian patients with AMI undergoing PCI.&#xD;
&#xD;
      All eligible AMI patients receive loading dose of ticagrelor 180 mg plus aspirin 300 mg,&#xD;
      following ticagrelor 90 mg twice daily plus aspirin 100 mg daily during the index&#xD;
      hospitalization. Subsequently, to be randomly assigned into ticagrelor 90 mg and ticagrelor&#xD;
      60/45 mg twice daily in combination with aspirin 100 mg daily at discharge for at least&#xD;
      12-month period treatment.&#xD;
&#xD;
      The investigators focusing on the efficacy and safety endpoint, is net adverse clinical and&#xD;
      cerebrovascular events (NACCE), composite of all-cause mortality, myocardial infarction,&#xD;
      stroke, and major bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net adverse clinical and cerebral events (NACCE)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of all-cause death, myocardial infarction, stroke or major bleeding according to PLATO criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Clinically significant bleeding: a composite of major or minor bleeding according to PLATO criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a composite of cardiac death, myocardial infarction, or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual components of MACCE</measure>
    <time_frame>12 months</time_frame>
    <description>Indicated cardiac death, myocardial infarction, or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Indicated non-cardiac death, target lesion/vessel revascularization, stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor (PLATO) bleeding event</measure>
    <time_frame>12 months</time_frame>
    <description>By PLAtelet inhibition and patient Outcomes (PLATO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or minor (TIMI) bleeding event</measure>
    <time_frame>12 months</time_frame>
    <description>By the Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC bleeding from type 1 to 5</measure>
    <time_frame>12 months</time_frame>
    <description>By Bleeding Academic Research Consortium (BARC) definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature discontinuation of study drugs</measure>
    <time_frame>12 months</time_frame>
    <description>The patients cannot tolerate to be continued study drugs, due to bleeding event, or side effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor 90mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard strategy group receive ticagrelor 90mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 60/45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-escalation strategy group receive ticagrelor 60 mg twice daily or 45mg twice daily if patients with body weight &lt;60kg, or age &gt;75 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.</description>
    <arm_group_label>Ticagrelor 90mg</arm_group_label>
    <other_name>Brilinta 90mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 60/45mg</intervention_name>
    <description>In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.</description>
    <arm_group_label>Ticagrelor 60/45mg</arm_group_label>
    <other_name>Brilinta 60/45mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients present with acute myocardial infarction undergoing PCI.&#xD;
&#xD;
          -  Patients receive potent DAPT (Ticagrelor 180 mg loading dose followed by 90 mg twice&#xD;
             daily plus Aspirin 300 mg loading dose followed by 100 mg daily).&#xD;
&#xD;
          -  Patients provide written informed consent prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of transient ischemic attack or stroke.&#xD;
&#xD;
          -  History of upper gastrointestinal bleeding in recent 6 months.&#xD;
&#xD;
          -  Renal dysfunction defined as serum creatinine &gt; 2.5 mg/dl.&#xD;
&#xD;
          -  Severe hepatic dysfunction defined as serum transaminase &gt; 3 times normal limit.&#xD;
&#xD;
          -  On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).&#xD;
&#xD;
          -  Bleeding tendency.&#xD;
&#xD;
          -  Thrombocytopenia defined by platelet &lt; 100,000/ml.&#xD;
&#xD;
          -  Anemia defined by hemoglobin &lt; 10 g/dl.&#xD;
&#xD;
          -  Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction&#xD;
             with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin,&#xD;
             nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and&#xD;
             telithromycin.&#xD;
&#xD;
          -  Known severe chronic obstructive pulmonary disease or bradycardia (sick sinus syndrome&#xD;
             (SSS) or high degree AV block without pacemaker protection).&#xD;
&#xD;
          -  Contraindication for study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moo Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital, Busan, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moo Hyun Kim, M.D.</last_name>
    <phone>+82-51-240-2976</phone>
    <email>kimmh@dau.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai De Jin, M.D.</last_name>
    <phone>+8619117712582</phone>
    <email>jincaide1118@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DongA University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moo Hyun Kim, M.D.</last_name>
      <phone>+82-51-240-2976</phone>
      <email>kimmh@dau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Moo Hyun Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J. 2015;79(11):2452-60. doi: 10.1253/circj.CJ-15-0112. Epub 2015 Sep 16.</citation>
    <PMID>26376600</PMID>
  </reference>
  <reference>
    <citation>Jin C, Kim MH, Bang J, Serebruany V. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Cardiology. 2017;138(4):201-206. doi: 10.1159/000478000. Epub 2017 Aug 16.</citation>
    <PMID>28810251</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Moo Hyun Kim</investigator_full_name>
    <investigator_title>Professor, Dept. of Cardiology Dong-A University Hospital</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>De-escalation strategy</keyword>
  <keyword>East Asian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

